We are excited to share our recent participation in the EACR2024 #event in Rotterdam, where laura luberto and Alessia Muzi presented the results of one of our latest #research projects in cancer therapy.
Our research focuses on the HER3 receptor, a crucial member of the ErbB receptor family, known for its role in cellular regulation and oncogenesis, particularly in mediating drug resistance. This makes HER3 a strategic target for innovative cancer therapies with a dual approach.
1. #GeneticVaccine: We developed a genetic cancer vaccine using DNA vectors encoding HER3, administered via electro-gene-transfer (DNA-EGT) in BALB/NeuT mice. This method induces a specific immune response against tumor cells, establishing long-term immunologic memory to prevent relapse.
2. #MonoclonalAntibodies: Concurrently, we explored a monoclonal antibody strategy, generating a series of hybridomas against human ErbB3. These antibodies were selected for their ability to effectively inhibit the ErbB3-mediated signaling pathway.
The DNA-EGT vaccination elicited a robust immune response against HER3, significantly preventing cancer onset and slowing tumor progression in therapeutic models.
The anti-ErbB3 monoclonal antibodies demonstrated antitumor properties in vitro and in vivo, effectively modulating cancer cell growth.
Our approach paves the way for further innovations, including:
– Vectorized antibody expression systems for sustained in vivo antibody production.
– Development of antibody-drug conjugates (ADCs) or bispecific antibodies for targeted and potent therapies against HER3-expressing tumors.
This dual-strategy approach not only highlights the therapeutic potential of targeting HER3 but also demonstrates the versatility and effectiveness of our innovative methodologies.
We are proud of our team’s work and the results presented at EACR2024.
